News stories about Regeneron Pharmaceuticals (NASDAQ:REGN) have trended somewhat positive recently, according to Accern Sentiment Analysis. Accern identifies positive and negative news coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Regeneron Pharmaceuticals earned a daily sentiment score of 0.23 on Accern’s scale. Accern also gave news headlines about the biopharmaceutical company an impact score of 45.2027049147353 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
These are some of the media stories that may have effected Accern’s analysis:
- Regeneron Pharmaceuticals, Inc. (REGN) Shares Bought by Aperio Group LLC (expressnewsline.com)
- Pfizer's (PFE) Besponsa Gets FDA Nod with a Boxed Warning (finance.yahoo.com)
- Regeneron Pharmaceuticals, Inc. (REGN) Chairman P Roy Vagelos Sells 1,305 Shares (americanbankingnews.com)
- P Roy Vagelos Sells 15,191 Shares of Regeneron Pharmaceuticals, Inc. (REGN) Stock (americanbankingnews.com)
- Insider Selling: Regeneron Pharmaceuticals, Inc. (REGN) Chairman Sells 10,986 Shares of Stock (americanbankingnews.com)
Regeneron Pharmaceuticals (NASDAQ REGN) traded up 0.85% during trading on Friday, reaching $467.98. 549,722 shares of the company’s stock were exchanged. Regeneron Pharmaceuticals has a 12 month low of $325.35 and a 12 month high of $543.55. The firm has a market cap of $49.62 billion, a price-to-earnings ratio of 46.95 and a beta of 1.66. The firm’s 50-day moving average price is $489.51 and its 200-day moving average price is $430.92.
Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported $4.17 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.67 by $1.50. Regeneron Pharmaceuticals had a return on equity of 25.58% and a net margin of 22.05%. The company had revenue of $1.47 billion for the quarter, compared to analyst estimates of $1.36 billion. During the same period in the previous year, the company posted $2.82 earnings per share. The firm’s revenue was up 21.2% on a year-over-year basis. On average, equities research analysts anticipate that Regeneron Pharmaceuticals will post $14.85 EPS for the current year.
A number of equities research analysts recently issued reports on the stock. BMO Capital Markets increased their target price on shares of Regeneron Pharmaceuticals from $412.00 to $421.00 and gave the stock a “hold” rating in a research report on Monday, May 15th. Canaccord Genuity set a $522.00 price objective on shares of Regeneron Pharmaceuticals and gave the stock a “buy” rating in a report on Monday, August 14th. Leerink Swann reissued an “outperform” rating and set a $580.00 price objective (up previously from $573.00) on shares of Regeneron Pharmaceuticals in a report on Wednesday, August 9th. Vetr lowered shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $408.86 price objective on the stock. in a report on Monday, April 24th. Finally, UBS AG set a $489.00 price objective on shares of Regeneron Pharmaceuticals and gave the stock a “buy” rating in a report on Friday, May 5th. Two research analysts have rated the stock with a sell rating, thirteen have given a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company. The company has a consensus rating of “Hold” and a consensus target price of $495.59.
In related news, Chairman P Roy Vagelos sold 1,305 shares of the company’s stock in a transaction on Thursday, August 17th. The stock was sold at an average price of $470.00, for a total transaction of $613,350.00. Following the completion of the sale, the chairman now owns 329,543 shares in the company, valued at $154,885,210. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Robert J. Terifay sold 21,147 shares of the company’s stock in a transaction on Friday, June 16th. The shares were sold at an average price of $468.19, for a total value of $9,900,813.93. Following the sale, the executive vice president now owns 72,043 shares of the company’s stock, valued at approximately $33,729,812.17. The disclosure for this sale can be found here. Insiders sold 84,404 shares of company stock worth $40,303,792 over the last three months. Corporate insiders own 10.40% of the company’s stock.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
